相似文献
1
Dynamic Changes in the Nigrostriatal Pathway in the MPTP Mouse Model of Parkinson's Disease.
Parkinsons Dis. 2017;2017:9349487. doi: 10.1155/2017/9349487. Epub 2017 Jul 31.
2
Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Neurobiol Dis. 2012 Mar;45(3):1051-67. doi: 10.1016/j.nbd.2011.12.024. Epub 2011 Dec 14.
3
Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Neuroscience. 2006 Jun 19;140(1):67-76. doi: 10.1016/j.neuroscience.2006.02.007. Epub 2006 Mar 14.
4
Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Neuroscience. 2011 Apr 28;180:256-71. doi: 10.1016/j.neuroscience.2011.02.027. Epub 2011 Feb 16.
5
Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease.
Neuroscience. 2019 Aug 21;414:8-27. doi: 10.1016/j.neuroscience.2019.06.006. Epub 2019 Jun 18.
6
Transgenic supplementation of SIRT1 fails to alleviate acute loss of nigrostriatal dopamine neurons and gliosis in a mouse model of MPTP-induced parkinsonism.
F1000Res. 2015 May 27;4:130. doi: 10.12688/f1000research.6386.1. eCollection 2015.
7
Increased susceptibility of G-protein coupled receptor 6 deficient mice to MPTP neurotoxicity.
Neuroscience. 2016 Nov 19;337:218-223. doi: 10.1016/j.neuroscience.2016.09.021. Epub 2016 Sep 17.
8
Quantitative whole-brain 3D imaging of tyrosine hydroxylase-labeled neuron architecture in the mouse MPTP model of Parkinson's disease.
Dis Model Mech. 2019 Nov 22;12(11):dmm042200. doi: 10.1242/dmm.042200.
9
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
J Neurochem. 2002 Aug;82(3):615-24. doi: 10.1046/j.1471-4159.2002.00990.x.
10
Differential ultrastructural alterations in the Vglut2 glutamatergic input to the substantia nigra pars compacta/pars reticulata following nigrostriatal dopamine loss in a progressive mouse model of Parkinson's disease.
Eur J Neurosci. 2021 Apr;53(7):2061-2077. doi: 10.1111/ejn.14894. Epub 2020 Jul 28.
引用本文的文献
1
State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic.
OpenNano. 2022 Nov-Dec;8:100078. doi: 10.1016/j.onano.2022.100078. Epub 2022 Sep 10.
2
1,4-dihydroxy-2-naphthoic acid prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced motor function deficits.
Behav Pharmacol. 2025 Feb 1;36(1):40-46. doi: 10.1097/FBP.0000000000000806. Epub 2024 Dec 12.
3
Characterizing the adult zebrafish model of Parkinson's disease: a systematic review of dynamic changes in behavior and physiology post-MPTP administration.
Front Neurosci. 2024 Sep 10;18:1432102. doi: 10.3389/fnins.2024.1432102. eCollection 2024.
4
Time association study on a sub-acute mouse model of Parkinson's disease.
Heliyon. 2024 Jul 4;10(13):e34082. doi: 10.1016/j.heliyon.2024.e34082. eCollection 2024 Jul 15.
5
Lactoferrin: neuroprotection against Parkinson's disease and secondary molecule for potential treatment.
Front Aging Neurosci. 2023 Sep 5;15:1204149. doi: 10.3389/fnagi.2023.1204149. eCollection 2023.
6
Low-Field Magnetic Stimulation Alleviates MPTP-Induced Alterations in Motor Function and Dopaminergic Neurons in Male Mice.
Int J Mol Sci. 2023 Jun 19;24(12):10328. doi: 10.3390/ijms241210328.
7
Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson's disease.
J Neuroinflammation. 2023 Jun 22;20(1):147. doi: 10.1186/s12974-023-02830-w.
8
RIPK1-Induced A1 Reactive Astrocytes in Brain in MPTP-Treated Murine Model of Parkinson's Disease.
Brain Sci. 2023 Apr 27;13(5):733. doi: 10.3390/brainsci13050733.
9
The deficiency of Maged1 attenuates Parkinson's disease progression in mice.
Mol Brain. 2023 Feb 11;16(1):22. doi: 10.1186/s13041-023-01011-3.
10
Deficiency of miR-29a/b1 leads to premature aging and dopaminergic neuroprotection in mice.
Front Mol Neurosci. 2022 Oct 6;15:978191. doi: 10.3389/fnmol.2022.978191. eCollection 2022.
本文引用的文献
1
Glial Cells and Their Function in the Adult Brain: A Journey through the History of Their Ablation.
Front Cell Neurosci. 2017 Feb 13;11:24. doi: 10.3389/fncel.2017.00024. eCollection 2017.
2
Neurotoxic reactive astrocytes are induced by activated microglia.
Nature. 2017 Jan 26;541(7638):481-487. doi: 10.1038/nature21029. Epub 2017 Jan 18.
3
New Transgenic Mouse Lines for Selectively Targeting Astrocytes and Studying Calcium Signals in Astrocyte Processes In Situ and In Vivo.
Neuron. 2016 Dec 21;92(6):1181-1195. doi: 10.1016/j.neuron.2016.11.030. Epub 2016 Dec 8.
4
Parkinson's disease: 4 big questions.
Nature. 2016 Oct 27;538(7626):S17. doi: 10.1038/538S17a.
5
Two hundred steps.
Nature. 2016 Oct 27;538(7626):S2-S3. doi: 10.1038/538S2a.
6
Pathogenic Upregulation of Glial Lipocalin-2 in the Parkinsonian Dopaminergic System.
J Neurosci. 2016 May 18;36(20):5608-22. doi: 10.1523/JNEUROSCI.4261-15.2016.
7
Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic Mice.
Int J Mol Sci. 2016 Jan 26;17(2):151. doi: 10.3390/ijms17020151.
8
Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease.
Glia. 2016 Mar;64(3):386-95. doi: 10.1002/glia.22935. Epub 2015 Oct 29.
9
Tiagabine Protects Dopaminergic Neurons against Neurotoxins by Inhibiting Microglial Activation.
Sci Rep. 2015 Oct 26;5:15720. doi: 10.1038/srep15720.
10
Neuroinflammation in Parkinson's disease and its potential as therapeutic target.
Transl Neurodegener. 2015 Oct 12;4:19. doi: 10.1186/s40035-015-0042-0. eCollection 2015.
Zotero 插件
